Iberdomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Iberdomide hydrochloride’s likelihood of approval (LoA) and phase transition for Multiple Myeloma (Kahler Disease) took place on 26 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Iberdomide hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Iberdomide hydrochloride overview
Iberdomide hydrochloride (CC-220) is under development for the treatment of systemic lupus erythematosus, relapsed/refractory multiple myeloma, aggressive B-cell lymphoma, B-cell lymphoma, unspecified B-cell lymphomas, T-cell lymphoma, natural killer (NK)-cell non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), marginal zone lymphoma (MZL), extranodal marginal zone b-cell lymphoma (mucosa-associated lymphoid tissue or malt-lymphoma, nodal marginal zone b-cell lymphoma, splenic marginal zone b-cell lymphoma, mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL), Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma, and classical Hodgkin lymphoma (CHL). The drug candidate is administered orally. It targets cereblon (CRBN) and inhibits CRBN ubiquitination. The drug candidate is an immunomodulatory imide drug (IMiD). It was also under development for cutaneous lupus erythematosus, systemic sclerosis and chronic cutaneous sarcoidosis.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
Quick View Iberdomide hydrochloride LOA Data
|Highest Development Stage|